Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : FP-045
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I/ Phase II
Recipient : Foresee Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Foresee Pharmaceuticals and TRPharm Announce License and Co-Development Agreement
Details : Under the terms of this partnership, Foresee and TRPharm will collaborate to initially expedite the development of FP-045 in Fanconi Anemia. Turkey and the surrounding region has a high prevalence Fanconi Anemia as well as other rare diseases.
Brand Name : FP-045
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 23, 2022
Lead Product(s) : FP-045
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I/ Phase II
Recipient : Foresee Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?
Reset All
